A Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Canagliflozin (TA-7284) in Patients With Diabetic Nephropathy
Latest Information Update: 10 Apr 2023
At a glance
- Drugs Canagliflozin (Primary)
- Indications Diabetic nephropathies
- Focus Registrational; Therapeutic Use
- Sponsors Mitsubishi Tanabe Pharma Corporation
Most Recent Events
- 02 Sep 2021 Status changed from active, no longer recruiting to completed.
- 09 Apr 2020 Status changed from recruiting to active, no longer recruiting.
- 21 Feb 2018 New trial record